Russian Heart Failure Journal 2011year Clinical and prognostic importance of hyperuricemia at chronic heart failure of elderly people

To access this material please log in or register

Register Authorize

Clinical and prognostic importance of hyperuricemia at chronic heart failure of elderly people

Larina V. N., Bart B. Ya., Brodsky M. S.
State Budgetary Educational Institution of Higher Professional Education, “N.I. Pirogov Russian National Research Medical University” of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: hyperuricemia, clinics, eldery age, prognostication, CHF

DOI: 10.18087/rhfj.2011.5.1557

Relevancy. Many provisions concerning practical value of hyperuricemia at CHF, especially with elderly age patients, stay ambiguous and not clear enough. Objective. Evaluation of clinical and prognostic value of hyperuricemia at CHF, elderly age patients. Materials and methods. The study included 248 CHF II–IV FC patients; they were divided into two groups depending on hyperuricemia evidence or absence (level of the uric acid serum ≥360 mcM / l). Results. Hyperuricemia was revealed at 47.6 % of patients of 60 years old and over; it was associated with increased creatinine level (r=–0.19, p=0.011), decreased glomerular filtration rate (r=0.21, p<0.001), high FC CHF (r=–0.28, p<0.001), lack of АРА II (r=0.14, p=0.032), low ejection fraction of left ventricle (r=0.13, p=0.042), increase of end-systolic dimension of the left ventricle (r=–0.13, p=0.045), increased Рsyst pulmonary artery (r=–0.16, p=0.021) and hospitalization rate (r=–0.17, p=0.005). Increased uric acid level (≥490 mcM / l) in blood serum at CHF disease may be considered as one of the markers of unfavorable progress notes and patients prognostication.
  1. Bos M, Koudstaal P, Hofman A et al. Uric acid is a risk factor for myocardial infarction and stroke. The Rotterdam study. Stroke. 2006;37 (6):1503–1507.
  2. Kim S, Guevara J, Kim K et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61 (7):885–892.
  3. Krishan E. Hyperuricemia and incident heart failure. Circ Heart Fail. 2009;2 (6):556–562.
  4. Hare J, Johnson R. Uric acid predicts clinical outcomes in heart failure. Insights regarding the role of xantine oxidase and uric acid in disease pathophysiology. Circulation. 2003;107 (15):1951–1953.
  5. Pascual-Figal D, Hurtado-Martinez J, Redondo B et al. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail. 2007 May; 9 (5):518–524.
  6. Baker J, Krishnan E, Chen L, Schumacher H. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118 (8):816–826.
  7. Сторожаков Г. И., Гендлин Г. Е. Основные направления в лечении больных с хронической сердечной недостаточностью (руководство для врачей терапевтов врачей общей практики). – М.: Миклош. 2008. – 312 с.
  8. Cowie MR, Fox KF, Wood DA et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J. 2002;23 (11):877–885.
  9. Pulignano G, del Sindaco D, Tavazzi L et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: date from a large nationwide cardiology database (IN–CHF Registry). Am Heart J. 2002;143 (1):45–55.
  10. Zhang W, Doherty M, Pascual E et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65 (10):1301–1311.
  11. Насонов Е. Л. Ревматология. Национальное руководство. – М.: ГЭОТАР–Медиа. 2008. – 737с.
  12. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130 (6):461–470.
  13. Комитет экспертов Всероссийского научного общества кардиологов и Научного общества нефрологов России. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Кардиоваскулярная терапия и профилактика. 2008;7 (6):Приложение 3 к журналу.
  14. Ogino K, Kato M, Furuse Y, Kinugasa Y. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010;3 (1):73–81.
  15. Ruggiero C, Cherubini A, Ble A et al. Uric acid and inflammatory markers. Eur Heart J. 2006;27 (10):1174–1181.
  16. Duan X, Ling F. Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? Med Hypotheses. 2008;70 (3):578–581.
  17. Терещенко С. Н, Демидова И. В. Почечная функция при хронической сердечной недостаточности у больных пожилого и старческого возра­ста. Журнал Сердечная Недостаточность. 2002;3 (5):251–256.
  18. Резник Е. В, Гендлин Г. Е, Сторожаков Г. И, Волынкина В. М. Почечная гемодинамика у больных хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2007;8 (3):118–125.
  19. Reungjui S, Roncal C, Mu W et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol. 2007;18 (10):2724–2731.
  20. Ochiai M, Baretto A, Oliveira M et al. Uric acid renal excretion and renal insufficiency in decompensated severe heart failure. Eur J Heart Fail. 2005;7 (4):468–474.
  21. Leyva F, Chua T, Ancer S, Coats A. Uric Acid in chronic heart failure: a measure of the anaerobic threshold. Metabolism. 1998;47 (9):1156–1159.
  22. Gullu H, Erdogan D, Caliskan M et al. Elevated serum acid level impair coronary microvascular function in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2007;9 (5):466–468.
  23. Wurzner G, Gerster J, Chiolero A, Maillard M et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens. 2001;19 (10):1855–1860.
  24. Hamada T, Hisatome I, Kinugasa Y, Matsubara K et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med. 2002;41 (10):793–797.
  25. Kittleson M, John M, Bead V et al. Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart. 2007;93 (3):365–367.
  26. Терещенко С. Н, Левчук Н. Н, Дроздов В. Н, Моисеев В. С. Уровень мочевой кислоты в крови больных с постинфарктной сердечной недостаточностью. Терапевтический Архив. 2000;72 (9):57–60.
  27. Cукманова И. А, Яхонтов Д. А. Метаболические показатели, маркеры функции эндотелия и оксидативного стресса у пациентов пожилого возраста с систолической и диастолической ХСН. Журнал Сердечная Недостаточность. 2009;10 (2):111–114.
  28. Anker SD, Coats AJ. Metabolic, functional, and haemodynamic staging for CHF? Lancet. 1996 Dec 7;348 (9041):1530–1531.
  29. Anker S, Doehner N, Raucchaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional and hemodynamic staging. Circulation. 2003;107 (15):1991–1997.
  30. Wasserman A, Shnell M, Boursi B, Guzner-Gur H. Prognostic significance of serum uric acid in patients admitted to the department of medicine. Am J Med Sci. 2010;339 (1):15–21.
  31. Jankowska E, Ponikowska B, Majda J, Zymlinski R et al. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol. 2007;115 (2):151–155.
  32. Zoccali C, Maio R, Mallamaci F et al. Uric Acid and Endothelial Dysfunction in Essential Hypertension. J Am Soc Nephrol. 2006;17 (5):1466–1471.
  33. Bettencourt P, Ferreira A, Dias P et al. Predictors of prognosis in patients with stable mild to moderate heart failure. J Card Fail. 2000;6 (4):306–313.
  34. De Groote P, Mouquet F, Lamblin N et al. Serum uric acid is a powerful predictor of survival in patients with stable chronic heart failure receiving beta-blocker therapy. Circulation. 2007;116:II 650.
  35. Alcaino H, Greig D, Chiong M et al. Serum acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail. 2008;10 (7):646–651.
  36. Гладких А. С, Савина Н. М, Кудинова С. П, Байдина О. И, Сидоренко Б. А. Повторные госпитализации больных с хронической сердечной недостаточностью по данным одногодичного наблюдения. Кардиология. 2009;49 (6):31–35.
  37. Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. Physiology (Bethesda). 2005;20:125–33.
  38. Doehner W, Rauchhous M, Ponikovski P et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005;46 (6):1019–1026.
Larina V. N., Bart B. Ya., Brodsky M. S. Clinical and prognostic importance of hyperuricemia at chronic heart failure of elderly people. Russian Heart Failure Journal. 2011;12(5):277-281.

To access this material please log in or register

Register Authorize
Ru En